STERIS is concentrating formulated-chemistries manufacturing into a new North Carolina center while the Healthcare franchise keeps compounding on consumables and services rather than lumpy capital shipments. The first quarter of fiscal 2027 showed that installed-base pull-through is still doing the economic work. Management held full-year adjusted earnings guidance even as the plant lifted the capital budget.
The tension is mix, not demand. Recurring revenue reached $1.2 billion. Healthcare capital barely grew, and contract-sterilization volume stayed light as device makers worked down inventory. Gross margin still expanded because price and productivity outran inflation and tariffs.
Reported diluted earnings rose to $2.04. Adjusted diluted earnings rose to $2.59. Free cash flow cooled on a weaker working-capital contribution even as the company bought back $100 million of stock. The question for the next several quarters is whether Applied Sterilization Technologies volume re-accelerates after destocking, and whether the North Carolina spend stays a capacity story rather than a cash-conversion drag.